Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PB006 vs Tysabri in RRMS
NCT04115488Phase 3Completed
- Sponsor
- Polpharma Biologics
- Start
- Oct 2019
- Primary completion
- Aug 2021
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 3 trial of natalizumab in relapsing-remitting multiple sclerosis (RRMS), sponsored by Polpharma Biologics. Started Oct 2019; status: completed.
02
Drugs
natalizumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT04115488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04115488.